September 29, 2026 — Hauts-de-France, France Glyx Therapeutics took part in the morning session “Financing your innovation: from idea to market”, held at Eurasanté with Banque Populaire du Nord. Financing a biotech company, from the idea to the market, is a demanding path. Exchanges with the health and finance ecosystem are valuable to build a […]
September 2026 — Amiens, France At Glyx Therapeutics, our molecule, an anionic lipidic oligosaccharide, targets Alzheimer’s disease and tauopathies. Our innovation does not stop there: we are developing the production of this molecule at pharmaceutical (GMP) grade, entirely following green chemistry principles, with electrosynthesis and mechanosynthesis. Sustainable Day, Amiens, November 5, 2026 Glyx Therapeutics will […]
September 2026 — Amiens, France Glyx Therapeutics has been selected as a finalist of the i-Lab 2026 innovation competition, which supports the creation of deeptech companies from public research results and is backed by the France 2030 programme. Recognition for an early-stage biotech Created in December 2025, Glyx Therapeutics is developing a small molecule, administered […]
